Prevents nausea and vomiting. ANDA 77851, held by Natco Pharma Ltd. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77851 (Ondansetron Hydrochloride), held by Natco Pharma Ltd, was first approved by FDA on Jun 25, 2007, with 4 approved supplements and 0 published complete response letters.
Ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2. initial and repeat courses of moderately emetogenic cancer chemotherapy. radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2007 | Original application | Approved | None posted |
| Ondansetron HydrochlorideEQ 4MG BASE · tablet;oral | Ondansetron Hydrochloride | Rx |
| Ondansetron HydrochlorideEQ 8MG BASE · tablet;oral | Ondansetron Hydrochloride | Rx |
| Feb 14, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 31, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 31, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 17, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 25, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters